Half Year 2022 Hikma Pharmaceuticals PLC Earnings Call Transcript

Aug 04, 2022

Click here to view more HKMPF transcripts

Aug 04, 2022 / 09:30AM GMT
Operator

Hello, everyone and welcome to the Hikma Interim Results 2022. My name is Emily and I will be moderating the call today. (Operator Instructions)

I will now hand over the call to our host, Susan Ringdal from Hikma. Please go ahead, Susan.

Susan Ringdal - Hikma Pharmaceuticals PLC - EVP of Strategic Planning & Global Affairs

Good morning, everyone. Thank you for joining our call today. Hopefully, you will have seen the pre-recorded presentation that's posted up on our website. So the format for today will just be Q&A.

In the room with US today we have our Executive Chairman and CEO, Said Darwazah; CFO, Khalid Nabilsi; our Vice Chairman, Mazen Darwazah; The President of Generics, Brian Hoffmann and the President of Injectables, Riad Mishlawi.

Said is going to kick off just saying a few words and then we're going to open the floor for questions.

Said Samih Taleb Darwazah - Hikma Pharmaceuticals PLC - Executive Chairman & CEO

Thank you. Thank you, Susan and good morning everybody.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.